2022
Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study
Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, Zheng K, Syal G, Ha C, Fleshner P, McGovern D, Sauk J, Limketkai B, Dulai P, Boland B, Eisenstein S, Ramamoorthy S, Melmed G, Mahadevan U, Sandborn W, Ohno-Machado L. Comparative Safety and Effectiveness of Biologic Therapy for Crohn’s Disease: A CA-IBD Cohort Study. Clinical Gastroenterology And Hepatology 2022, 21: 2359-2369.e5. PMID: 36343846, DOI: 10.1016/j.cgh.2022.10.029.Peer-Reviewed Original ResearchConceptsTNF-α antagonistsRisk of hospitalizationUstekinumab-treated patientsCrohn's diseaseSerious infectionsLower riskMulticenter cohortInflammatory bowel disease-related surgeryTumor necrosis factor α antagonistsNecrosis factor α antagonistsDisease-related surgeryHigher comorbidity burdenVedolizumab-treated patientsNew biologic agentsPropensity-score matchingComorbidity burdenCause hospitalizationAdult patientsBiologic therapyCohort studyPrior hospitalizationBiologic agentsΑ antagonistsBiologic classesComparative safety
2021
No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy
Picetti D, Kim J, Zhu W, Sandborn W, Jairath V, Singh S. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy. Digestive Diseases And Sciences 2021, 67: 3115-3123. PMID: 34797442, PMCID: PMC9117569, DOI: 10.1007/s10620-021-07301-x.Peer-Reviewed Original ResearchConceptsAnti-metabolite therapyCrohn's diseaseCox proportional hazards analysisCD-related hospitalizationCD-related surgeryAdministrative claims databaseProportional hazards analysisCorticosteroid useTreatment escalationClaims databaseClinical benefitResidual confoundingHigh riskPatientsDisease severityMonotherapyDiseaseKey covariatesTherapyHazard analysisOutcomesRiskEscalationMethodsPatientsHospitalization